October 2, 2026

Praxis Precision Medicines, Inc (PRAX) Investor Outlook: A High-Stakes Bet with 124% Potential Upside

In the dynamic world of biotechnology, Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stands out as a compelling, albeit risky, opportunity for investors seeking exposure to groundbreaking therapies for central nervous..

Auna SA (AUNA) Stock Analysis: Uncovering a 40% Potential Upside in the Healthcare Sector

Auna SA (AUNA), a Luxembourg-based healthcare service provider, has been making waves in the medical care facilities industry with its operations spanning across Mexico, Peru, and Colombia. Known for its..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Unpacking a Potential 166% Upside

Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of small-molecule drugs targeting organ fibrosis and inflammation. Despite its..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating the Biotech Wave with Strategic Insight

In the competitive realm of biotechnology, Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stands as a pivotal player, offering essential products that drive the development of drug therapies, vaccines, and diagnostics..

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unraveling a 202% Potential Upside in the Biotech Sector

Capricor Therapeutics, Inc. (NASDAQ: CAPR) has captured the attention of investors with its staggering potential upside of 202.01%, according to recent analyst ratings. As a clinical-stage biotechnology company, Capricor is..

Valneva SE (VALN) Stock Analysis: Navigating 107.63% Potential Upside Amid Challenging Metrics

Valneva SE (VALN), a notable player in the biotechnology sector, operates out of France with a keen focus on developing vaccines for infectious diseases with significant unmet needs. Despite facing..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech with Nearly 99% Upside Potential

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is capturing significant attention in the biotechnology sector, primarily due to its promising potential upside of nearly 99%. As a clinical-stage biopharmaceutical company, Trevi focuses..

Arbutus Biopharma (ABUS) Stock Analysis: Exploring a 17.57% Potential Upside in Biotechnology

Arbutus Biopharma Corporation (NASDAQ: ABUS) stands as a compelling player in the biotechnology sector, particularly for those investors looking to delve into the dynamic world of infectious disease therapeutics. With..

iRadimed Corporation (IRMD) Stock Report: Exploring a 38% Upside Potential in the Healthcare Sector

Investors with an eye on the healthcare sector should pay close attention to iRadimed Corporation (NASDAQ: IRMD), a prominent player in the medical devices industry. Headquartered in Orlando, Florida, iRadimed..

Claritev Corporation (CTEV) Stock Analysis: Healthcare Innovator with a 115% Upside Potential

Claritev Corporation (NASDAQ: CTEV), a key player in the healthcare sector, has caught the attention of investors, and for good reason. With a potential upside of 115.86%, this company is..

Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 517% Potential Upside in the Biotech Arena

For investors with a keen eye on the biotechnology sector, Upstream Bio, Inc. (NASDAQ: UPB) presents a particularly intriguing opportunity. This clinical-stage biotech company, headquartered in Waltham, Massachusetts, is making..

Syndax Pharmaceuticals (SNDX) Stock Analysis: Unveiling a 106% Potential Upside in Biotech Innovation

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX), a burgeoning player in the biotechnology sector, presents a compelling investment opportunity with a significant potential upside. With a market capitalization of $1.61 billion, this..

LifeMD, Inc. (LFMD) Stock Analysis: Exploring a 185% Upside with Strong Buy Ratings

LifeMD, Inc. (NASDAQ: LFMD), a key player in the burgeoning telehealth sector, stands out with its potential upside of 185.09%, driven by a strong consensus of buy ratings from analysts...

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: A Biotech Powerhouse with Promising Revenue Growth Amidst Volatile Market

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a trailblazer in the biotechnology sector, is capturing investor attention with its innovative approach to treating solid tumor cancers. The company’s market cap stands at..

Definitive Healthcare Corp. (DH) Stock Analysis: Can the 103% Upside Potential Attract Investors?

Definitive Healthcare Corp. (NASDAQ: DH), a key player in the health information services industry, offers a compelling narrative for investors navigating the healthcare sector. Founded in 2011 and headquartered in..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: Eyeing a 58% Upside in a Challenging Biotech Landscape

Arcus Biosciences, Inc. (NASDAQ: RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapies, is generating buzz among investors with its potential for significant upside. Despite operating within the volatile biotechnology..

Xencor, Inc. (XNCR) Stock Analysis: Exploring a 26.83% Potential Upside in the Biotechnology Sector

Xencor, Inc. (XNCR), a dynamic player in the biotechnology sector, is drawing attention from investors with its innovative approach to drug development, particularly in the fields of cancer and autoimmune..

Akso Health Group (AHG) Stock Analysis: Challenges and Opportunities in China’s Medical Distribution Sector

Akso Health Group (AHG), a player in China’s burgeoning healthcare sector, presents an intriguing case for investors navigating the complex landscape of medical distribution. With a market capitalization of $873.84..

Phibro Animal Health Corporation (PAHC) Stock Analysis: A 22.67% Upside Potential Beckons Investors

Phibro Animal Health Corporation (NASDAQ: PAHC) presents a compelling opportunity for investors seeking exposure to the healthcare sector, specifically in the niche of animal health and mineral nutrition. With a..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Potential 45% Upside Amid Strong Buy Ratings

Nurix Therapeutics, Inc. (NASDAQ: NRIX), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its promising pipeline of therapies targeting cancer and inflammatory diseases. With a market..

Search

Funds

October 2, 2026

Search

Funds

October 2, 2026

FTSE 100

Funds